Treatment

Patient receiving a specialist antifungal medicine delivery at home

Getting specialist antifungal medicines delivered to your home: a guide to NHS homecare

Clinician reviewing immune-suppressing medicines and blood test results alongside lung and Aspergillus imagery.

Immune-Suppressing Medicines and Aspergillosis: When Does Treatment Change the Risk?

Scientific illustration showing amphotericin B disrupting an Aspergillus fungal cell membrane during research into antifungal resistance.

Amphotericin B resistance in Aspergillus: protecting an important treatment for the future

Person reducing respiratory infection risk through ventilation, handwashing, vaccination and mask use

Respiratory Infections and Aspergillosis: Reducing Your Risk and Knowing When to Seek Help

Medical illustration showing nasal polyps, inflamed lungs and dupilumab targeting inflammation throughout the connected airway

Could One Biologic Treat Nasal Polyps, Asthma and ABPA?

Illustration of Aspergillus fumigatus spores interacting with the bronchial airway lining beside a DNA strand representing the ZNF77 gene variant.

Lung Colonisation by Aspergillus fumigatus Is Influenced by a ZNF77 Gene Variant

Illustration of lungs, Aspergillus and an intravenous infusion representing rezafungin research for chronic pulmonary aspergillosis

Rezafungin for chronic pulmonary aspergillosis: encouraging early evidence while clinical trial continues

Older patient reviews inhalers, tablets and other medicines with a clinical pharmacist.

Are all your medicines still helping? A guide to polypharmacy and medication reviews

Illustration showing how Xolair (omalizumab) treats allergic bronchopulmonary aspergillosis (ABPA) by blocking IgE antibodies and reducing allergic inflammation in the lungs.

Why Can an Asthma Drug Help ABPA? Understanding Xolair (Omalizumab)

Vaccination protects people living with aspergillosis and other chronic lung diseases against serious respiratory infections.

Vaccinations for People Living with Aspergillosis